Method for ameliorating or preventing arrhythmic risk associated with cardiomyopathy
View Patent ↗A method for reducing arrhythmic risk associated with cardiomyopathy includes administering a composition containing NAD + or a mitochondrial targeted antioxidant to an individual in need thereof.
1. A method for reducing arrhythmic risk associated with cardiomyopathy characterized by an enlarged chamber, comprising the step of administering a mitochondrial targeted antioxidant to an individual in need thereof.
2. The method of claim 1 , wherein the amount of antioxidant is effective to reduce arrhythmic risk.
3. The method of claim 1 , wherein the antioxidant prevents or lowers reduction in sodium channel current (I Na ) by reducing or suppressing mitochondrial ROS production.
4. The method of claim 1 , wherein the antioxidant is administered orally or intravenously.
5. The method of claim 1 , wherein the individual is suffering from arrhythmia.
6. The method of claim 1 , wherein the antioxidant comprises at least one member selected from the group consisting of a powder, a tablet, a capsule, a solution, a suspension, and an injectable formulation.
7. The method of claim 1 , wherein the antioxidant comprises 2-(2,2,6,6-Tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chloride (MitoTEMPO).
8. A method for reducing arrhythmic risk and restoring the cardiac sodium current to a normal level in an individual with cardiomyopathy characterized by an enlarged chamber, comprising the step of administering a mitochondrial targeted antioxidant to an individual in need thereof.
9. The method of claim 8 , wherein the amount of antioxidant is effective to reduce arrhythmic risk.
10. The method of claim 8 , wherein the antioxidant prevents or lowers reduction in sodium channel current (I Na ) by reducing or suppressing mitochondrial ROS production.
11. The method of claim 8 , wherein the antioxidant is administered orally or intravenously.
12. The method of claim 8 , wherein the individual is suffering from arrhythmia.
13. The method of claim 8 , wherein the antioxidant comprises at least one member selected from the group consisting of a powder, a tablet, a capsule, a solution, a suspension, and an injectable formulation.
14. The method of claim 8 , wherein the antioxidant comprises 2-(2,2,6,6-Tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chloride (MitoTEMPO).
15. A method for reducing arrhythmic risk in an individual with cardiomyopathy characterized by an enlarged chamber and a cardiac ejection fraction of less than 50%, comprising the step of administering a mitochondrial targeted antioxidant to an individual in need thereof.
16. The method of claim 15 , wherein the amount of antioxidant is effective to reduce arrhythmic risk.
17. The method of claim 15 , wherein the antioxidant prevents or lowers reduction in sodium channel current (I Na ) by reducing or suppressing mitochondrial ROS production.
18. The method of claim 15 , wherein the antioxidant is administered orally or intravenously.
19. The method of claim 15 , wherein the individual is suffering from arrhythmia.
20. The method of claim 15 , wherein the antioxidant comprises at least one member selected from the group consisting of a powder, a tablet, a capsule, a solution, a suspension, and an injectable formulation.
21. The method of claim 15 , wherein the antioxidant comprises 2-(2,2,6,6-Tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chloride (MitoTEMPO).